{
  "id": "5c73acec7c78d69471000086",
  "type": "factoid",
  "question": "Losigamone can be used for treatment of which disease?",
  "ideal_answer": "Losigamone is sometimes used as an add-on therapy for epilepsy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
    "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
    "http://www.ncbi.nlm.nih.gov/pubmed/9421300",
    "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
    "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
    "http://www.ncbi.nlm.nih.gov/pubmed/20650103",
    "http://www.ncbi.nlm.nih.gov/pubmed/14704462",
    "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
    "http://www.ncbi.nlm.nih.gov/pubmed/12972172",
    "http://www.ncbi.nlm.nih.gov/pubmed/15112861",
    "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
    "http://www.ncbi.nlm.nih.gov/pubmed/22696384"
  ],
  "snippets": [
    {
      "text": "Losigamone add-on therapy for focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In recent years, many newer AEDs have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the efficacy outcomes, results did show that participants taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.76, 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16, 95% CI 1.28 to 3.67). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS: The results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Losigamone add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In recent years, many newer AEDs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the efficacy outcomes, results did show patients taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.76; 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16; 95% CI 1.28 to 3.67). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS: The results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For topiramate, felbamate, retigabine, losigamone and stiripentol, GABAAR modulation is one of several possible antiseizure mechanisms. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683707",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Losigamone add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the efficacy outcomes, results did show patients taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.75; 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16; 95% CI 1.28 to 3.67). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS: The results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549021",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21429248",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This is supplemented by the mechanisms of drug action at these important anticonvulsant targets for classical and clinically relevant compounds (e.g. phenytoin, ethosuximide) as well as some important second generation drugs (e.g. gabapentin, levetiracetam) and novel experimental agents (e.g. retigabine, losigamone, safinamide). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15638775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: The influence of the new antiepileptic drug losigamone (CAS 112856-44-7/123783-52-8) on the pharmacokinetics of a combined oral contraceptive containing ethinylestradiol (CAS 57-63-6) and levonorgestrel (CAS 797-63-7) was investigated in 16 healthy women.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15112861",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The objective of the study was to investigate the efficacy and safety of two different dosages of Losigamone (LSG) in add-on treatment of partial seizures.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12972172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the study's results, LSG is an effective and safe add-on drug for refractory partial epilepsy in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12972172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS\nThe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\nTo investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SELECTION CRITERIA\nRandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS\nThe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AUTHORS' CONCLUSIONS\nThe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\nTo investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the efficacy outcomes, results did show patients taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.75; 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16; 95% CI 1.28 to 3.67).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five drugs (carbamazepine, diazepam, phenobarbital, phenytoin and valproate), currently used in the treatment of epileptic patients, were tested together with losigamone, a recently developed anticonvulsant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20650103",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A subgroup analysis according to different doses of losigamone showed that a higher dose of losigamone (1500 mg/d) is associated with a greater reduction in seizure frequency than lower doses, but is also associated with more dropouts due to adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Losigamone is a novel anticonvulsant the mechanism of action of which is not known.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9421300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\nTo investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SELECTION CRITERIA\nRandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the study's results, LSG is an effective and safe add-on drug for refractory partial epilepsy in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12972172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Losigamone add-on therapy for partial epilepsy.The results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Losigamone add-on therapy for partial epilepsy.The results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Losigamone add-on therapy for focal epilepsy.The results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Efficacy and safety of Losigamone in partial seizures: a randomized double-blind study.The objective of the study was to investigate the efficacy and safety of two different dosages of Losigamone (LSG) in add-on treatment of partial seizures. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12972172",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Perspectives of losigamone in epilepsy treatment.Patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704462",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic Reviews 2012, Issue 6).<br><b>OBJECTIVES</b>: To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>SEARCH METHODS</b>: We searched the Cochrane Epilepsy Group Specialized Register (16 February 2015), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 16 February 2015) and MEDLINE (Ovid, 1946 to 16 February 2015).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical trial, losigamone proved to have satisfactory effectiveness and good tolerance in the treatment of partial and secondary generalized seizures.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704462",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26661741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the efficacy outcomes, results did show patients taking losigamone were significantly more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.75; 95% CI 1.14 to 2.72), but associated with a significant increase of treatment withdrawal when compared with those taking placebo (RR 2.16; 95% CI 1.28 to 3.67).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696384",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "epilepsy"
}